Sialic acid-binding immunoglobulin-like lectin-6 (SIGLEC6) is increased by hypoxia and inflammation in trophoblasts

OBJECTIVES: SIGLEC6, a human-specific transmembrane receptor, is highly expressed in placenta. SIGLEC6 is elevated in maternal circulation preceding preeclampsia and in women with preeclampsia, correlating with disease severity. This study aimed to investigate the regulatory mechanisms of placental SIGLEC6 and its involvement in processes associated with preeclampsia pathogenesis. STUDY DESIGN: To determine cell source, SIGLEC6 was measured in (cyto)trophoblasts, syncytiotrophoblasts, and extravillous trophoblasts. We then assessed the impact of hypoxia (1% vs 8% Oxygen), inflammatory cytokines (Interleukin 6 (IL-6) or Tumour Necrosis Factor alpha (TNFα)), or Brefeldin A (impairs protein trafficking) on SIGLEC6 production/secretion. We also assessed whether treatment with recombinant SIGLEC6 induced endothelial dysfunction in human umbilical vein endothelial cells (HUVECs). MAIN OUTCOMES MEASURES: SIGLEC6 expression across trophoblast subpopulations; its regulation under hypoxia, inflammation and Brefeldin A treatment; and its effect on endothelial dysfunction markers. RESULTS: SIGLEC6 was expressed in all cell types and upregulated during differentiation of human trophoblast stem cells into syncytiotrophoblasts and extravillous trophoblasts. Exposure of syncytiotrophoblasts to hypoxia elevated SIGLEC6 expression (p = 0.0079), and protein secretion (p = 0.0079). Similarly, pro-inflammatory cytokines increased SIGLEC6 expression (IL-6: p = 0.0016, and TNFα: p = 0.0015) and protein secretion (IL-6: p = 0.002, and TNFα: p = 0.01) from syncytiotrophoblasts. Treatment with Brefeldin A reduced SIGLEC6 secretion in cell lysates (p = 0.001) and conditioned media (p = 0.02). Recombinant SIGLEC6 had no effect on pro- and anti-angiogenic factors and endothelial dysfunction markers in HUVECs. CONCLUSION: SIGLEC6 expression is induced by hypoxia and inflammation in syncytialised hTSCs, but recombinant SIGLEC6 did not induce endothelial dysfunction in HUVECs.

Authors

Institutions

Publication Details

Journal
Pregnancy Hypertension
Published
2026-08-14
DOI
https://doi.org/10.1016/j.preghy.2026.101503
Primary Topic
Glycosylation and Glycoproteins Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sialic acid-binding immunoglobulin-like lectin-6 (SIGLEC6) is increased by hypoxia and inflammation in trophoblasts

Cíara Murphy, Manju Kandel, Stephen Tong, Georgia P Wong et al.
Pregnancy Hypertension
Glycosylation and Glycoproteins Research
article

Sialic acid-binding immunoglobulin-like lectin-6 (SIGLEC6) is increased by hypoxia and inflammation in trophoblasts

Cíara Murphy, Manju Kandel, Stephen Tong, Georgia P Wong, Tuong-Vi Nguyen, Anna Nguyen, Ping Cannon, Lucy Bartho, Tu'’uhevaha J. Kaitu'u-Lino, Natalie J. Hannan
article en

Abstract

OBJECTIVES: SIGLEC6, a human-specific transmembrane receptor, is highly expressed in placenta. SIGLEC6 is elevated in maternal circulation preceding preeclampsia and in women with preeclampsia, correlating with disease severity. This study aimed to investigate the regulatory mechanisms of placental SIGLEC6 and its involvement in processes associated with preeclampsia pathogenesis. STUDY DESIGN: To determine cell source, SIGLEC6 was measured in (cyto)trophoblasts, syncytiotrophoblasts, and extravillous trophoblasts. We then assessed the impact of hypoxia (1% vs 8% Oxygen), inflammatory cytokines (Interleukin 6 (IL-6) or Tumour Necrosis Factor alpha (TNFα)), or Brefeldin A (impairs protein trafficking) on SIGLEC6 production/secretion. We also assessed whether treatment with recombinant SIGLEC6 induced endothelial dysfunction in human umbilical vein endothelial cells (HUVECs). MAIN OUTCOMES MEASURES: SIGLEC6 expression across trophoblast subpopulations; its regulation under hypoxia, inflammation and Brefeldin A treatment; and its effect on endothelial dysfunction markers. RESULTS: SIGLEC6 was expressed in all cell types and upregulated during differentiation of human trophoblast stem cells into syncytiotrophoblasts and extravillous trophoblasts. Exposure of syncytiotrophoblasts to hypoxia elevated SIGLEC6 expression (p = 0.0079), and protein secretion (p = 0.0079). Similarly, pro-inflammatory cytokines increased SIGLEC6 expression (IL-6: p = 0.0016, and TNFα: p = 0.0015) and protein secretion (IL-6: p = 0.002, and TNFα: p = 0.01) from syncytiotrophoblasts. Treatment with Brefeldin A reduced SIGLEC6 secretion in cell lysates (p = 0.001) and conditioned media (p = 0.02). Recombinant SIGLEC6 had no effect on pro- and anti-angiogenic factors and endothelial dysfunction markers in HUVECs. CONCLUSION: SIGLEC6 expression is induced by hypoxia and inflammation in syncytialised hTSCs, but recombinant SIGLEC6 did not induce endothelial dysfunction in HUVECs.

Pregnancy HypertensionVol. 45
Mercy Hospital for Women (AU)
Australian Research Council, National Health and Medical Research Council
Openalex Percentile: Top 17%
Glycosylation and Glycoproteins Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.